Compounded GLP-1s in 2026: What the FDA Changes Mean for Your Prescription
The FDA proposed removing semaglutide from the compounding shortage list. Here's what that means for your treatment, your options, and your next steps.
If you're currently taking compounded semaglutide or tirzepatide — or considering starting — the regulatory landscape shifted significantly in 2026. The FDA has moved to restrict compounding of these medications, and the changes affect millions of patients. Here's what's actually happening, what it means for your treatment, and what your options are.
What Changed
In early 2026, the FDA formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list. In plain language: the FDA determined that the national shortages of these medications have been resolved, which removes the primary legal basis that allowed large-scale compounding pharmacies (503B facilities) to produce them.
The key timeline:
- April 2026: FDA published the proposed rule
- June 29, 2026: Public comment period closes
- Post-June 2026: Final decision expected — could maintain, modify, or finalize the restrictions
Several major compounding laboratories (including ProRx and BPI Labs) ceased production of compounded semaglutide in early 2026, and the FDA issued warning letters to 30+ telehealth companies for violations related to compounded GLP-1 marketing.
What It Means for Patients
If you're currently on compounded semaglutide: Your treatment isn't immediately affected, but you should have a plan. Some compounding pharmacies are still operating under existing state licenses (503A pharmacies are less directly affected by the 503B bulks list change). However, the overall supply of compounded GLP-1 medications is tightening.
If you're considering starting compounded GLP-1s: Compounded options are still available from licensed providers, but the window may be narrowing. This is a reason to choose providers with strong pharmacy relationships and multiple sourcing options — not a reason to rush into treatment with an unvetted provider.
503A vs. 503B: Why It Matters Now
Understanding the difference between these two pharmacy types has become genuinely important for patients:
- 503A pharmacies are state-licensed compounding pharmacies that prepare medications based on individual patient prescriptions. The FDA's 503B bulks list change doesn't directly affect 503A pharmacies — they operate under different legal authority. However, states may impose their own restrictions.
- 503B pharmacies are FDA-registered "outsourcing facilities" that can produce larger quantities without patient-specific prescriptions. These are the facilities most directly affected by the bulks list change.
Providers that work with both 503A and 503B pharmacies have more supply chain flexibility as the regulatory environment evolves.
Your Options Going Forward
The GLP-1 medication landscape in 2026 actually has more options than ever — even with the compounding restrictions:
Brand-Name Medications (FDA-Approved)
- Injectable Wegovy: $349–$499/mo through NovoCare (self-pay), potentially $0–$25 with commercial insurance
- Wegovy pill: $149–$299/mo through NovoCare
- Foundayo: $149–$399/mo through LillyDirect (approved April 2026)
- Zepbound: $349–$599/mo through LillyDirect
Compounded Medications (Still Available)
- Licensed 503A pharmacies continue preparing patient-specific compounded medications
- Some 503B facilities are still operating while the regulatory process unfolds
- Prices range from $99–$300/month depending on provider and dose
Insurance Coverage (Expanding)
- More commercial insurance plans are covering GLP-1s for weight loss in 2026
- Manufacturer savings cards can reduce brand-name costs to $25–$149/month for eligible commercially insured patients
What to Do Right Now
- Don't panic. Compounded GLP-1s are still available. The regulatory process is ongoing, not finalized.
- Ask your provider about their pharmacy sourcing. Providers with 503A pharmacy partners have more insulation from the 503B bulks list change.
- Explore brand-name alternatives. Foundayo at $149/mo and the Wegovy pill at $149/mo are now price-competitive with many compounded options.
- Check your insurance. Coverage for GLP-1 weight loss medications has expanded significantly — you may qualify for brand-name options at lower cost than you expect.
- Don't stockpile. Buying months of medication in advance from unverified sources creates safety and storage risks.